Product Information
ATELVIA DR 35 MG TABLET is a brand product labeled by Allergan, Inc., priced at $63.8494 per EA under NDC 00430097903. Its NADAC has been published 404 times since Nov 28, 2013.
FDA first approved this application on Oct 8, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the risedronate sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
30.1; 4.9 mg/1; mg/1
Manufacturer
Allergan, Inc.NDC
00430097903
Classification
Brand
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
RISEDRONATE SODIUM HEMIPENTAHYDRATE; RISEDRONATE SODIUM MONOHYDRATEApproval Type
New Drug (NDA)
FDA Application
NDA022560FDA Approved
10/8/2010
TE Code
AB
On Market Since
12/1/2010
Pharmacological Classes
Price Statistics
The NADAC for ATELVIA DR 35 MG TABLET has been published 404 times since Nov 28, 2013, and over the history we have for it it has risen 82.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $63.8494 per EA |
|---|---|
| All-time high | $64.0500 (Jul 15, 2026) |
| All-time low | $35.0716 (Nov 28, 2013) |
| 52-week high | $64.0500 |
| 52-week low | $63.2246 |
| Median price | $56.0674 |
| Average price | $54.9477 |
| Largest weekly change | +14.9% (Jan 14, 2015) |
| Weeks tracked | 404 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 53% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ATELVIA DR 35 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ATELVIA DR 35 MG TABLET, manufactured by Allergan, Inc., is $63.8494 per EA (NDC 00430097903), effective Aug 19, 2026.
How has the price of ATELVIA DR 35 MG TABLET changed over time?
Over the history we have for it, the NADAC for ATELVIA DR 35 MG TABLET has risen 82.1%. It has been tracked across 404 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ATELVIA DR 35 MG TABLET?
Since Nov 28, 2013, the NADAC for ATELVIA DR 35 MG TABLET has ranged from a low of $35.0716 (Nov 28, 2013) to a high of $64.0500 (Jul 15, 2026), with a median of $56.0674 per EA.
Are there cheaper alternatives to ATELVIA DR 35 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISEDRONATE SOD DR 35 MG TAB, is $29.8417 per EA — about 53% below ATELVIA DR 35 MG TABLET.
Who manufactures ATELVIA DR 35 MG TABLET?
ATELVIA DR 35 MG TABLET (NDC 00430097903) is labeled by Allergan, Inc., and CMS classifies it as a brand product.